Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147205 | 0.91 | MC4R (0.48) | CHRM1PIM1PIM2CHRM2CHRM4 | |
| SCHEMBL13147155 | 0.81 | MC4R (0.58) | MC4R | |
| SCHEMBL13147183 | 0.81 | CHRM1 (0.42) | CHRM1CHRM2CHRM4CHRM3MC4R | |
| SCHEMBL13147213 | 0.80 | MC4R (0.43) | PIM1PIM2MC4R | |
| SCHEMBL13147146 | 0.79 | MC4R (0.40) | MC4R | |
| SCHEMBL13147109 | 0.77 | MC4R (0.43) | PIM1PIM2MC4R | |
| SCHEMBL13147295 | 0.76 | MC4R (0.43) | PIM1PIM2MC4R | |
| SCHEMBL13147302 | 0.75 | MC4R (0.41) | CHRM1PIM1PIM2MC4R | |
| SCHEMBL13147328 | 0.74 | MC4R (0.52) | MC4R | |
| SCHEMBL13147189 | 0.73 | MC4R (0.51) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | CHRM1 74/4885PIM1 2617/4885PIM2 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.